Nerve Sheath Tumors of the Spine

Nerve sheath tumors represent 25-30% of all intradural spinal tumors, arising from Schwann cells (schwannomas, 70-80%) or nerve sheath fibroblasts (neurofibromas, 20-30%). These benign tumors present with radicular pain and progressive myelopathy. Schwannomas are typically solitary, encapsulated, and amenable to complete resection with nerve preservation, while neurofibromas are more infiltrative and associated with neurofibromatosis type 1.

Spinal Nerve Root Anatomy

Understanding nerve root anatomy is critical for surgical planning and minimizing post-operative deficits:

Tumor Pathology

View larger

Pathophysiology of Clinical Presentation

Symptom Progression

Physical Examination

Neurofibromatosis Screening

The Investigations section flags "Froin syndrome" as a marker of a complete CSF block but leaves the eponym undefined. It is worth developing because it remains a favourite viva and MCQ item and is the lumbar-puncture fingerprint of a nerve sheath tumour that has obstructed the spinal subarachnoid space.

Definition and triad. Froin syndrome (described by Georges Froin, 1903; also called the loculation or Nonne–Froin syndrome) is the constellation of cerebrospinal fluid changes found on lumbar puncture taken below a lesion that completely obstructs the spinal subarachnoid space. The classic triad is:

• Xanthochromia — yellow discoloration of the CSF produced by its very high protein content (and at times by prior microhaemorrhage).
• Markedly elevated protein (hyperproteinorrachia) — often greater than 1000 mg/dL, with a normal cell count. This dissociation of a high protein from a normal cell count is termed albuminocytological dissociation.
• Spontaneous hypercoagulation — the fluid clots on standing because of its high fibrinogen and protein load.

Mechanism. A large intradural extramedullary tumour (schwannoma, neurofibroma or meningioma) fills the canal and isolates the CSF caudal to it. Stagnant fluid distal to the block equilibrates with plasma proteins across leaky tumour vessels while normal CSF turnover ceases, so protein accumulates dramatically. Because the sample is drawn below the block, CSF glucose and cell count are typically normal — distinguishing Froin's picture from infective or malignant meningitis.

Why it matters clinically. Historically the block was demonstrated with the Queckenstedt test — manual jugular compression fails to raise lumbar CSF pressure when the subarachnoid space is obstructed. Today MRI has replaced both the Queckenstedt test and diagnostic lumbar puncture. Recognising a Froin-type CSF picture should prompt urgent whole-spine gadolinium MRI rather than repeated taps; lumbar puncture below a suspected complete block is best avoided because of the risk of neurological deterioration as fluid is withdrawn across the obstruction.

Surgical Indications

Surgical Approaches and Techniques

Nerve Root Preservation Strategies

Complications and Management

The management approaches above address the cervical, thoracic and lumbar spine, but sacral nerve sheath tumours behave differently and warrant their own note — the anatomy section already commits the S2–S5 roots (bladder, bowel and sexual function) to the "preserve if possible" column, and the roomy sacral canal lets a tumour grow silently.

Why they present late and large. The capacious sacral canal and pre-sacral space allow a schwannoma or neurofibroma to reach a very large size (a "giant" sacral tumour) before producing symptoms. Presentation is therefore insidious — vague low-back or pelvic pain, a palpable pre-sacral or buttock mass, or bladder, bowel and sexual dysfunction — rather than a sharp radiculopathy. CT shows a well-marginated lytic lesion that scallops and expands the sacrum with a smooth sclerotic rim, while MRI defines the intracanal and pre-sacral extent. The principal alternatives to exclude are chordoma (midline, calcifies, destroys bone) and metastasis.

Approach selection.

• Posterior (trans-sacral) approach suffices for tumours largely confined to the sacral canal and dorsal sacrum.
• Combined anterior (trans-abdominal or retroperitoneal) plus posterior approach, sometimes staged, is used for large pre-sacral components — the anterior stage controls the middle sacral and internal iliac vessels and protects the rectum, ureters and lumbosacral plexus before the posterior sacral resection.

The central trade-off — resection versus continence. Unlike an expendable thoracic sensory root, the sacral roots carry pelvic autonomic function, so gross total resection must be balanced against sphincter preservation. The working principles are:

• Preserving both S2 roots and at least one S3 generally maintains useful bladder, bowel and sexual function.
• Bilateral sacrifice of S2 and below typically produces a neurogenic bladder and bowel with sexual dysfunction.
• Unilateral sacrifice of an entire S1–S5 side is usually tolerated if the contralateral roots are intact.

For a benign schwannoma it is therefore acceptable to leave tumour on a functioning sphincter root (planned subtotal resection) rather than render the patient incontinent, reserving aggressive en-bloc excision for malignant lesions where oncological margins dominate. As elsewhere, intraoperative EMG and root stimulation guide which roots can be safely divided.

Global Epidemiology

• Nerve sheath tumours account for roughly 25–30% of intradural extramedullary spinal tumours; schwannomas predominate (70–80%) over neurofibromas.
• Peak incidence is in the fourth to sixth decades with no strong sex predilection (unlike spinal meningioma, which is markedly female-predominant).
• Most are sporadic and solitary. Multiplicity should prompt evaluation for a tumour-predisposition syndrome — NF1, NF2, or schwannomatosis (including SMARCB1/LZTR1-related disease).
• MPNST is rare overall but its lifetime risk rises to roughly 8–13% in NF1, making new pain or rapid growth in an NF1 patient a red flag worldwide.

Diagnostic & Syndrome Criteria (Side by Side)

Society Guidance & Practice Variation

• No single dedicated society "guideline" governs sporadic spinal nerve sheath tumour surgery; practice is guided by WHO CNS tumour classification (5th edition, 2021) for pathology and grading, NIH/revised international diagnostic criteria for NF1, and the Manchester criteria for NF2.
• Surgical principles are broadly concordant across AANS/CNS (US), the British Association of Spine Surgeons / SBNS (UK), EANS (Europe) and EFORT teaching: gross total microsurgical resection with neural preservation for symptomatic or growing tumours, observation with interval MRI for small asymptomatic lesions.
• WHO/NF management is increasingly delivered through specialist neurofibromatosis multidisciplinary clinics in high-resource settings, with genetic counselling and whole-neuraxis surveillance imaging.

Registry & Surveillance Notes

• Unlike arthroplasty, there is no large international implant registry for these tumours; outcome data derive from single-centre and multi-institutional surgical series and from national NF natural-history cohorts.
• High-resource settings: routine MRI with gadolinium, intraoperative neuromonitoring, microsurgical and minimally invasive corridors, and access to SRS and MDT NF clinics.
• Limited-resource settings: later presentation (larger tumours, established myelopathy), reliance on CT or non-contrast MRI, fewer neuromonitoring resources, and a lower threshold for open laminectomy with fusion where minimally invasive instrumentation is unavailable. The core operative principle — safe maximal resection with neural preservation — remains universal.

Nerve sheath tumour surgery is mature, but several decisions remain genuinely contested and are favourite viva discussion points.

• Routine vs selective intraoperative neuromonitoring. Triggered EMG and SSEP/MEP undeniably aid root identification, and in the largest series monitoring tracked with higher gross-total resection rates (79% vs 66%). However, no randomised trial demonstrates that monitoring reduces permanent deficits, and complication rates were similar with and without it. Practice ranges from mandatory for every intradural case to selective use for motor-root lesions.
• Extent of resection of the parent root. Classic teaching is to preserve the root of origin, yet historical data show the parent root is frequently already non-functional and sacrifice of even C5–T1 or L3–S1 roots produces a detectable deficit in only about a quarter of cases. The modern compromise is intracapsular debulking with functional preservation when stimulation confirms a live motor root, and en bloc removal when it does not.
• Prophylactic fusion after facetectomy. There is no consensus threshold. Many surgeons fuse after greater than 50% unilateral facet resection or any bilateral facetectomy, but minimally invasive far-lateral corridors have removed giant dumbbell tumours with no instrumentation, challenging the assumption that wide bony exposure mandates fusion.
• Management of asymptomatic and NF-associated tumours. Whether to operate on small asymptomatic lesions, and how aggressively to treat the multiple tumours of NF1/NF2 and schwannomatosis, is individualised. Most centres observe small stable lesions and operate selectively on symptomatic or growing ones, reserving prophylactic surgery for radiological progression.
• Role of stereotactic radiosurgery (SRS). SRS is established for intracranial schwannomas but its role for spinal nerve sheath tumours is limited to poor surgical candidates, residual/recurrent disease, or multiple NF-related lesions; durable high-level evidence is lacking and surgery remains first-line for accessible symptomatic tumours.
• MPNST adjuvant therapy. The benefit of radiotherapy and chemotherapy is uncertain. Foundational data showed no clear survival benefit, while more recent practice favours adjuvant radiotherapy for local control after marginal margins; complete resection remains the only consistently prognostic intervention.

1. Seppälä MT, Haltia MJ, Sankila RJ, Jääskeläinen JE, Heiskanen O. Long-term outcome after removal of spinal schwannoma: a clinicopathological study of 187 cases. J Neurosurg. 1995;83(4):621-626. PMID 7674010.

2. Conti P, Pansini G, Mouchaty H, Capuano C, Conti R. Spinal neurinomas: retrospective analysis and long-term outcome of 179 consecutively operated cases and review of the literature. Surg Neurol. 2004;61(1):34-43. PMID 14706374.

3. Jeon JH, Hwang HS, Jeong JH, Park SH, Moon JG, Kim CH. Spinal schwannoma; analysis of 40 cases. J Korean Neurosurg Soc. 2008;43(3):135-138. PMID 19096620.

4. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57(10):2006-2021. PMID 3082508.

5. Kim P, Ebersold MJ, Onofrio BM, Quast LM. Surgery of spinal nerve schwannoma. Risk of neurological deficit after resection of involved root. J Neurosurg. 1989;71(6):810-814. PMID 2585070.

6. Safaee MM, Lyon R, Barbaro NM, et al. Neurological outcomes and surgical complications in 221 spinal nerve sheath tumors. J Neurosurg Spine. 2016;26(1):103-111. PMID 27472744.

7. Poblete J, Martinez Anda JJ, Rebollar Mendoza AA, et al. Minimally invasive surgical technique for the management of giant dumbbell spinal schwannoma. J Neurol Surg A Cent Eur Neurosurg. 2023;84(3):219-226. PMID 34911086.

8. WHO Classification of Tumours Editorial Board. Central Nervous System Tumours. 5th ed. Lyon: IARC; 2021.

9. Klekamp J, Samii M. Surgery of Spinal Tumors. Berlin: Springer-Verlag; 2007.

Related pages: Schwannoma and Neurofibroma for the two lesions in full, including the histology and the peripheral (non-spinal) presentations; Malignant Peripheral Nerve Sheath Tumour for the transformation this page screens against; Neurofibromatosis for the syndromes and the 2021 revised criteria in detail, and for the dystrophic scoliosis that accompanies paraspinal plexiform disease; Intradural Extramedullary Tumours for the wider differential at that compartment and Metastatic Spine Disease for the commonest competing diagnosis; MRI Neurography for the imaging signs; and Cauda Equina Syndrome for the presentation a lumbosacral lesion can produce.